Acute Psychotropic Effects of Oral Cannabis Extract with a Defined Content of Δ9-Tetrahydrocannabinol (THC) in Healthy Volunteers

R. M. Kaufmann; B. Kraft; R. Frey; D. Winkler; S. Weiszenbichler; C. Bäcker; S. Kasper; H. G. Kress

doi:10.1055/s-0029-1237397

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2010; 43(1): 24-32
DOI: 10.1055/s-0029-1237397

Original Paper

Acute Psychotropic Effects of Oral Cannabis Extract with a Defined Content of Δ⁹-Tetrahydrocannabinol (THC) in Healthy Volunteers

R. M. Kaufmann¹ , B. Kraft² , R. Frey¹ , D. Winkler¹ , S. Weiszenbichler¹ , C. Bäcker¹ , S. Kasper¹ , H. G. Kress²

¹Division of Biological Psychiatry, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
²Division of Special Anesthesia and Pain Therapy, Department of Anesthesia, General Intensive Care and Pain Control, Medical University of Vienna, Vienna, Austria

Abstract

Introduction: The medical use of cannabinoids is limited mainly by their undesirable effects. With respect to acute psychotropic effects, the aim of this study is the comparison of an oral cannabis extract and low-dose diazepam in a cross-over experiment in drug-naïve healthy women.

Methods: Sixteen healthy females participated in this randomized, double-blind, active comparator-controlled, single-dose, balanced 2-way cross-over study. Cannabis extract with standardised Δ⁹-tetrahydrocannabinol (THC) content (20 mg) or active placebo (5 mg diazepam) was administered orally. Subjects were assessed by self- and observer-rated visual analogue scales (VAS), the brief psychiatric rating scale (BPRS) and three psychomotor tests up to 6 h after administration.

Results: VAS showed significantly elevated fatigue, drowsiness, dizziness, and “feeling high” after cannabis as compared to baseline and diazepam. BPRS scores were significantly higher after cannabis intake. Only in one psychomotor test a decrease of psychomotor activity after cannabis was evident. One subject in the cannabis condition experienced severe transient psychotic symptoms.

Discussion: Orally administered cannabis produced significant central depressant side-effects compared to diazepam, mostly subjective effects (VAS) but marginal effects in psychomotor performance in 15 healthy females. Regarding the medical use of cannabis, a rigorous benefit-risk analysis and an exact psychiatric assessment before and during treatment are necessary.

Volltext

Referenzen

References

1 Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996; 91 1585-1614
2 Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. Acta Psychiatr Scand. 1989; 79 505-510
3 Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001; 178 101-106
4 Baigent M, Holme G, Hafner RJ. Self reports of the interaction between substance abuse and schizophrenia. Aust N Zealand J Psychiatry. 1995; 29 69-74
5 Barnett G, Licko V, Thompson T. Behavioral pharmacokinetics of marijuana. Psychopharmacology. 1985; 85 51-56
6 Bird KD, Boleyn T, Chesher GB. et al . Intercannabinoid and cannabinoid-ethanol interactions and their effects on human performance. Psychopharmacology. 1980; 71 181-188
7 Block RI, Erwin WJ, Farinpour R. et al . Sedative, stimulant, and other subjective effects of marijuana: relationships to smoking techniques. Pharmacol Biochem Behav. 1998; 59 405-412
8 Bond AJ, Lader MH. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974; 47 211-218
9 Borland RG, Nicholson AN. Immediate effects on human performance of a 1,5-benzodiazepine (clobazam) compared with the 1,4-benzodiazepines, chlordiazepoxide hydrochloride and diazepam. Br J Clin Pharmacol. 1975; 2 215-221
10 Campell FA, Tramer MR, Carroll D. et al . Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001; 323 13-16
11 Carney MWP, Bacelle L, Robinson B. Psychosis after cannabis abuse. BMJ. 1984; 288 1047
12 Chait LD, Pierri J. Effects of smoked marijuana on human performance: a critical review. In: Murphy LL, Bartke A (eds.) Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Boca Raton, CRC Press 1992: 387-423
13 Chaudry HR, Moss HB, Bashir A. et al . Cannabis psychosis following bhang ingestion. Br J Addiction. 1991; 86 1075-1081
14 Craft RM. Sex differences in behavioral effects of cannabinoids. Life Sci. 2005; 77 2471-2478
15 Curran HV. Benzodiazepines, memory and cognitive function. In: Trimble M, Hindmarch I (eds.) Benzodiazepines. Hampshire: Wrightson Biomedical Publishers 2000: 17-29
16 Curran HV, Brignell C, Fletcher S. et al . Cognitive and subjective dose-response effects of acute oral Δ⁹-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology. 2002; 164 61-70
17 Devane WA, Dysarz FA, Johnson MR. et al . Determination and characteristics of a cannabinoid receptor in rat brain. Mol Pharmacology. 1988; 34 605-613
18 Devane WA, Hanus L, Breuer A. et al . Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258 1946-1949
19 D’Souza DC, Perry E, MacDougall L. et al . The pychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 29; 2004 1558-1572
20 ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78; 2005 539-548
21 Fant RV, Heishman SJ, Bunker EB. et al . Acute and residual effects of marijuana in humans. Pharmacol Biochem Behav. 1998; 60 777-784
22 Favrat B, Menetrey A, Augsburger M. et al . Two cases of “cannabis acute psychosis” following the administration of oral cannabis. BMC Psychiatry. 2005; 5 17-22
23 Frey R, Decker K, Reinfried L. et al . Effect of rest on physicians` performance in an emergency department, objectified by electroencephalographic analyses and psychometric tests. Crit Care Med. 2002; 30 2322-2329
24 Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964; 86 1646-1647
25 Gerrard L, Wheeldon NM, McDevitt DG. Effect of combined atenolol and nifedipine administration on psychomotor performance in normal subjects. Eur J Clin Pharmacol. 1995; 48 229-233
26 Ghodse AH. Cannabis psychosis. Br J Addiction. 1986; 81 473-478
27 Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev. 2007; 17 347-361
28 Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alc Rev. 2003; 22 453-460
29 Grünberger J. [Psychodiagnostik des Alkoholkranken. Methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Article in German]. Maudrich, Wien, Austria 1977
30 Grünberger J, Linzmayer L, Dietzl M. et al . The effect of biologically-active light on the noo- and thymopsyche and on psychophysiological variables in healthy volunteers. Int J Psychophysiol. 1993; 15 27-37
31 Hall W, Solowij N. Long-term cannabis use and mental health. Br J Psychiatry. 1997; 171 107-108
32 Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998; 352 1611-1616
33 Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust NZ J Psychiatry. 2000; 34 468-475
34 Heishman SJ, Huestis MA, Henningfield JE. et al . Acute and residual effects of marijuana: profiles of plasma thc levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav. 1990; 37 561-565
35 Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol. 1980; 10 189-209
36 Holdcroft A, Maze M, Dore C. et al . A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006; 104 1040-1046
37 Imade AGT, Ebie JC. A retrospective study of symptom patterns of cannabis-induced psychosis. Acta Psychiatr Scand. 1991; 83 134-136
38 Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001; 178 116-122
39 Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag. 2001; 6 80-91
40 Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28 849-863
41 Kaufmann RM, Frey R, Battista HJ. et al . Flunitrazepam and driving ability. Fortschr Neurol Psychiatr [Article in German]. 2004; 72 503-515
42 Kopelowicz A, Vendura J, Libermann RP. et al . Consistency of brief psychiatric rating scale factor structure across a broad spectrum of schizophrenia patients. Psychopathology. 2007; 41 77-84
43 Kraft B, Frickey NA, Kaufmann RM. et al . Lack Of Analgesia By Oral Standardized Cannabis Extract On Acute Inflammatory Pain And Hyperalgesia In Volunteers. Anesthesiology. 2008; 109 101-110
44 Kreuz DS, Axelrod J. delta-9-Tetrahydrocannabinol: localization in body fat. Science. 1973; 179 391-393
45 Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001; 56 1059-1068
46 Linzmayer L, Arnold O, Saletu-Zylarz GM. et al . Daytime noopsychic and thymopsychic dysfunctions in nonorganic insomnia related to different mental disorders. Somnologie. 2002; 6 141-148
47 Mason AP, McBay AJ. Cannabis: pharmacology and interpretation of effects. J Forensic Sci. 1985; 30 615-631
48 Mason OJ, Morgan CJM, Stefanovic A. et al . The psychotomimetic states inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis. Schizophrenia Res. 2008; 103 138-142
49 Mattila MJ, Vanakoski J, Kalska H. et al . Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav. 1998; 59 917-923
50 McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag. 2005; 10 15A-22A
51 Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998; 359 1-18
52 Moore THM, Zammit S, Lingford-Hughes A. et al . Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370 319-328
53 Negrete JC. Psychological adverse effects of cannabis smoking: a tentative classification. CMAJ. 1973; 108 195-202
54 Nicholson AN, Turner C, Stone BM. et al . Effect of Δ⁹-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacology. 2004; 24 305-313
55 O’Leary DS, Block RI, Koeppel JA. et al . Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology. 2002; 26 802-816
56 Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmac Bull. 1988; 24 97-99
57 Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997; 74 129-180
58 Peters BA, Lewis EG, Dustman RE. et al . Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of Δ⁹-tetrahydrocannabinol. Psychopharmacology. 1976; 47 141-148
59 Pickworth WB, Rohrer MS, Fant RV. Effects of abused drugs on psychomotor performance. Exp Clin Psychopharmacol. 1997; 5 235-241
60 Ramaekers J, Kauert G, Theunissen E. et al . Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. 2009; 23 266-277
61 Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology. 2006; 188 425-466
62 Saletu B, Grünberger J, Cepko H. Pharmaco-EEG and psychometric studies with a novel selective benzodiazepine agonist/antagonist Ro-23-0364. Int J Clin Pharmacol Ther Toxicol. 1987; 25 421-437
63 Sheehan DV, Lecrubier Y, Sheehan KH. et al . The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 ((Suppl 20)) 22-33
64 SPSS Inc .SPSS for Windows. Release 15.0. Chicago, IL, USA 1989–2006
65 Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry. 1972; 27 133-136
66 Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry. 1993; 163 141-149
67 Tseng AH, Harding JW, Craft RM. Pharmacokinetic factors in sex differences in delta 9-tetrahydrocannabinol-induced behavioral effects in rats. Behav Brain Res. 2004; 154 77-83
68 Tunving K. Psychiatric effects of cannabis use. Acta Psychiatr Scand. 1985; 72 209-217
69 Turner JM, de Wit H. Menstrual cycle phase and responses to drugs of abuse. Drug and Alcohol Dependence. 2006; 84 1-13
70 Vachon L, Sulkowski A, Rich E. Marijuana effects on learning, attention, and time estimation. Psychopharmacologia. 1974; 39 1-11
71 Webb E, Ashton CH, Kelly P. et al . Alcohol and drug use in UK university students. Lancet. 1996; 348 922-925
72 Zajicek J, Fox P, Sanders H. et al . Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003; 362 1517-1526

Correspondence

R. M. KaufmannMD

Division of Biological Psychiatry

Department of Psychiatry and Psychotherapy

Medical University of Vienna

Waehringer Guertel 18–20

1090 Vienna

Austria

Telefon: +43/1/40400/35 68

Fax: +43/1/40400/30 99

eMail: rainer.kaufmann@meduniwien.ac.at